FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]

研究用のみ。 完全な免責事項 →

スタックライブラリ

Immune Restore Stack

Immune Supportintermediate

83

シナジー

83
Share
ペプチド

2

平均日用量mcg

11,500

レベル

intermediate

追加

May 17, 2026

概要

The Immune Restore Stack targets thymic-derived immunity — the immune system''s "training academy" that produces and educates T-cells. Both Thymosin Alpha-1 and Thymalin are thymic peptides, but they work through different mechanisms to restore immune competence that declines with age (immunosenescence). Thymalin is a polypeptide complex extracted from bovine thymic tissue and used extensively in Russian and Eastern European longevity medicine. It works broadly across the immune system — stimulating thymic function, restoring T-cell differentiation, and improving NK cell activity. Thymalin is used in 10-day intensive courses (rather than chronically) to "reset" thymic function, consistent with the bioregulator approach developed by Vladimir Khavinson. Thymosin Alpha-1 provides the ongoing immune calibration between Thymalin courses. It activates specific immune checkpoints — promoting Th1 immunity (cellular defense against viruses and abnormal cells) while modulating excessive Th2 activity (linked to allergic and autoimmune responses). With FDA-approved use in multiple countries for viral hepatitis and research use in cancer immunotherapy, Thymosin Alpha-1 has the most extensive human evidence base of any peptide immunomodulator. The protocol uses Thymalin in twice-yearly 10-day intensive courses to restore thymic function, with Thymosin Alpha-1 administered regularly between courses for ongoing immune calibration. This mirrors how both compounds were used in the landmark Soviet longevity studies that showed significant improvements in immune function and lifespan markers.

投与プロトコル

Thymosin Alpha-1

2x per week· subcutaneous

Thymosin Alpha-1について詳しく読む →

1,500 mcg

1回の投与あたり

Thymalin

daily (10-day course)· subcutaneous

Thymalinについて詳しく読む →

10,000 mcg

1回の投与あたり

目標と証拠

Immune restorationT-cell functionNK cell activityAutoimmune modulationAnti-aging immunity
証拠ランク:人間データ

警告

  • Thymalin availability is limited outside Eastern Europe. Both compounds require medical supervision.

Comments

Sign in to join the discussion

注意: このスタックはコミュニティから提出され、研究用のみです。Peptide Contactsは提出されたスタックの安全性や効果性を確認していません。使用するペプチドプロトコル前に常に資格のある医療専門家に相談してください。